MELISSA KROON: Open Payments
NPI 1962892240 · BOISE, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,590 in 68 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $817 · 2025 $1,590
Food & beverage: $1,590
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 13 | $388 |
| Regeneron Healthcare Solutions, Inc. | 8 | $206 |
| CSL Behring | 4 | $188 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $163 |
| GlaxoSmithKline, LLC. | 12 | $149 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $108 |
| Grifols USA, LLC | 4 | $94 |
| BioCryst US Sales Co., LLC | 3 | $80 |
| Amgen Inc. | 3 | $57 |
| Pharming Healthcare, Inc. | 2 | $40 |
Products named: FASENRA, DUPIXENT, TRELEGY ELLIPTA, TEZSPIRE, NEFFY, Hizentra, Prolastin-C Liquid, Andembry.
Industry payments across ID — which companies pay providers there.
